ESTRO 2024 - Abstract Book

S1705

Clinical - Lung

ESTRO 2024

Conclusion:

Our results support the use of SABR for lung metastasis from colorectal cancer, particularly when treatment is feasible at an early stage of metastatic disease, with a near-minimum BED 10 ≥110 Gy to the GTV or ITV. This retrospective study with consecutive inclusion is the first to show a precise dosimetric criteria based on GTV/ITV with an increase of LC in this known radioresistant histology. These results should be validated by a prospective study.

Keywords: SABR, metastases, colorectal cancer